Evolent Health Reiterates Q2 and Full Year Adjusted EBITDA Guidance Amid Lower-than-Expected Oncology Costs

Reuters

昨天

Evolent Health Reiterates Q2 and Full Year Adjusted EBITDA Guidance Amid Lower-than-Expected Oncology Costs

Evolent Health Inc. (NYSE: EVH) has reiterated its guidance for the second quarter and full year 2025, projecting Adjusted EBITDA of $33 million to $40 million for Q2 and $135 million to $165 million for the full year. The company noted that it is experiencing oncology cost trends below expectations, which has contributed to its confidence in meeting or exceeding these forecasts. John Johnson, Evolent's Chief Financial Officer, expressed optimism about achieving the upper end of the Q2 Adjusted EBITDA range if current trends continue through June. Additionally, Evolent Health announced a significant increase in its forecast for new revenue bookings heading into 2026, driven by accelerated business development activities. To support this growth, the company secured a Commitment Letter with Ares Management Credit funds, providing an option for additional non-dilutive capital to manage its 2025 Convertible Notes and support its expanding organic growth pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolent Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH14625) on June 20, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2544126691"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544126691\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2544126691?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-20 18:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544126691","market":"us","top_or_hot":-1,"title":"Evolent Health Reiterates Q2 and Full Year Adjusted EBITDA Guidance Amid Lower-than-Expected Oncology Costs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evolent Health Reiterates Q2 and Full Year Adjusted EBITDA Guidance Amid Lower-than-Expected Oncology Costs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EVH\">Evolent Health Inc</a>. (NYSE: EVH) has reiterated its guidance for the second quarter and full year 2025, projecting Adjusted EBITDA of $33 million to $40 million for Q2 and $135 million to $165 million for the full year. The company noted that it is experiencing oncology cost trends below expectations, which has contributed to its confidence in meeting or exceeding these forecasts. John Johnson, Evolent's Chief Financial Officer, expressed optimism about achieving the upper end of the Q2 Adjusted EBITDA range if current trends continue through June. Additionally, Evolent Health announced a significant increase in its forecast for new revenue bookings heading into 2026, driven by accelerated business development activities. To support this growth, the company secured a Commitment Letter with Ares Management Credit funds, providing an option for additional non-dilutive capital to manage its 2025 Convertible Notes and support its expanding organic growth pipeline.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolent Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH14625) on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evolent Health Reiterates Q2 and Full Year Adjusted EBITDA Guidance Amid Lower-than-Expected Oncology Costs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvolent Health Reiterates Q2 and Full Year Adjusted EBITDA Guidance Amid Lower-than-Expected Oncology Costs\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-20 18:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evolent Health Reiterates Q2 and Full Year Adjusted EBITDA Guidance Amid Lower-than-Expected Oncology Costs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EVH\">Evolent Health Inc</a>. (NYSE: EVH) has reiterated its guidance for the second quarter and full year 2025, projecting Adjusted EBITDA of $33 million to $40 million for Q2 and $135 million to $165 million for the full year. The company noted that it is experiencing oncology cost trends below expectations, which has contributed to its confidence in meeting or exceeding these forecasts. John Johnson, Evolent's Chief Financial Officer, expressed optimism about achieving the upper end of the Q2 Adjusted EBITDA range if current trends continue through June. Additionally, Evolent Health announced a significant increase in its forecast for new revenue bookings heading into 2026, driven by accelerated business development activities. To support this growth, the company secured a Commitment Letter with Ares Management Credit funds, providing an option for additional non-dilutive capital to manage its 2025 Convertible Notes and support its expanding organic growth pipeline.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolent Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH14625) on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1670628061.USD","symbol_name":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL7NpxMR:1","article_id":"2544126691","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544126691","pubTimestamp":1750415423,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Evolent Health Inc.  has reiterated its guidance for the second quarter and full year 2025, projecting Adjusted EBITDA of $33 million to $40 million for Q2 and $135 million to $165 million for the full year. The company noted that it is experiencing oncology cost trends below expectations, which has contributed to its confidence in meeting or exceeding these forecasts. John Johnson, Evolent's Chief Financial Officer, expressed optimism about achieving the upper end of the Q2 Adjusted EBITDA range if current trends continue through June. Additionally, Evolent Health announced a significant increase in its forecast for new revenue bookings heading into 2026, driven by accelerated business development activities. To support this growth, the company secured a Commitment Letter with Ares Management Credit funds, providing an option for additional non-dilutive capital to manage its 2025 Convertible Notes and support its expanding organic growth pipeline.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4135":"资产管理与托管银行","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU0971096721.USD":"富达环球金融服务 A","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","EVH":"Evolent Health Inc","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","ARES":"Ares Management L.P.","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4167":"医疗保健技术","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"由于肿瘤费用低于预期，Evolent Health重申第二季度和全年调整后EBITDA指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARES":0.9,"EVH":0.9},"content_text":"Evolent Health Reiterates Q2 and Full Year Adjusted EBITDA Guidance Amid Lower-than-Expected Oncology Costs\n    \n\nEvolent Health Inc. (NYSE: EVH) has reiterated its guidance for the second quarter and full year 2025, projecting Adjusted EBITDA of $33 million to $40 million for Q2 and $135 million to $165 million for the full year. The company noted that it is experiencing oncology cost trends below expectations, which has contributed to its confidence in meeting or exceeding these forecasts. John Johnson, Evolent's Chief Financial Officer, expressed optimism about achieving the upper end of the Q2 Adjusted EBITDA range if current trends continue through June. Additionally, Evolent Health announced a significant increase in its forecast for new revenue bookings heading into 2026, driven by accelerated business development activities. To support this growth, the company secured a Commitment Letter with Ares Management Credit funds, providing an option for additional non-dilutive capital to manage its 2025 Convertible Notes and support its expanding organic growth pipeline.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolent Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH14625) on June 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}